Increased frequency of the CTLA-4 49 A/G polymorphism in patients with acquired haemophilia A compared to healthy controls

Haemophilia

Volumn 14, Issue 2, 2008, Pages 355-360

  Pavlova, A ^a   Diaz Lacava, A ^b   Zeitler, H ^a   Satoguina, J ^a   Niemann, B ^a   Krause, M ^c   Scharrer, I ^a   Hoerauf, A ^d   Wienker, T ^b   Oldenburg, Johannes ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Acquired haemophilia; CTLA 4; Polymorphisms

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

ACQUIRED HEMOPHILIA A; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENETIC RISK; GENETIC VARIABILITY; HEMOPHILIA A; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; AUTOANTIBODIES; CASE-CONTROL STUDIES; FACTOR VIII; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEMOPHILIA A; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 40349114614     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2007.01618.x     Document Type: Article

References (39)

1. Shapiro SS, Hultin M. Acquired inhibitors to the blood coagulation factors. Thromb Haemost 1975; 1: 336-85.
2. Green D, Lechner K. A survey of 215 nonhaemophilic patients with inhibitors to factor VIII. Thromb Haemost 1981; 45: 200-3.
3. Hoyer LW. Factor VIII inhibitors. Curr Opin Hematol 1995; 2: 365-71.
4. Morrison AE, Ludlam CA. Acquired haemophilia and its treatment. Br J Haematol 1995; 89: 231-6.
5. Di Bona E, Schiavoni M, Castaman G, Ciavarella N, Rodeghiero F. Acquired hemophilia: Experience of two Italian centers with 17 new cases. Haemophilia 1997; 3: 183-8.
6. Bossi P, Cabane J, Ninet J et al. Acquired hemophilia due to factor VIII inhibitors in 34 patients. Am J Med 1998; 105: 400-8.
7. Baudo F, Mostarda G, De Cataldo F. Acquired factor VIII and factor IX inhibitors: Survey of the Italian Haemophilia Centers (AICE). Register of Acquired factor VIII/IX inhibitors. Haematologica 2003; 88 (Suppl. 12): 93-9.
8. Kessler CM, Nemes L. Acquired inhibitors to factor VIII. In: Rodriguez-Merchan EC, Lee C eds. Inhibitors in Patients with Haemophilia. Oxford: Blackwell Science Ltd, 2002: 98-112.
9. Ewenstein BM, Putnam KG, Bohn RL. Nonhemophilic inhibitors of coagulation. In: Consultative Hemostasis and Thrombosis. Kitchens CS, Alving BM, Kessler CM, eds. Philadelphia: Elsevier Science, WB Saunders Co, 2002: 75-90.
10. Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD, Bluestone JA. CTLA-4: A negative regulator of autoimmune disease. J Exp Med 1996; 184: 783-8.
11. Karandikar NJ, Vanderlugt CL, Bluestone JA, Miller SD. Targeting the B7/ CD28:CTLA-4 costimulatory system in CNS autoimmune disease. J Neuroimmunol 1998; 89: 10-8 (Review).
12. Maurer M, Loserth S, Kolb-Maurer A et al. A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1+49) alters T-cell activation. Immunogenetics 2002; 54: 1-8.
13. Eagar TN, Karandikar NJ, Bluestone JA, Miller SD. The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance. Eur J Immunol 2002; 32: 972-81.
14. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. CTLA-4 deficient mice exhibit massive lymphoproliferation and multi-organ lymphatic infiltration: A critical negative immunoregulatory role of CTLA-4. Immunity 1995; 3: 541-7.
15. Deichmann K, Heinzmann A, Bruggenolte E, Forster J, Kuehr J. An Mse I RFLP in the human CTLA4 promotor. Biochem Biophys Res Commun 1996; 225: 817-8.
16. Harper K, Balzano C, Rouvier E, Mattei M G, Luciani M F, Golstein P. CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J Immunol 1991; 147: 1037-44.
17. Ueda H, Howson JM, Esposito L et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423: 506-11.
18. Kotsa K, Watson PF, Weetman AP. A CTLA-4 gene polymorphism is associated with both Graves disease and autoimmune hypothyroidism. Clin Endocrinol 1997; 46: 551-4.
19. Donner H, Rau H, Walfish PG et al. CTLA-4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 143-6.
20. Braun J, Donner H, Siegmund T, Walfish PG, Usadel KH, Badenhoop K. CTLA-4 promoter variants in patients with Graves' disease and Hashimoto's thyroiditis. Tissue Antigens 1998; 51: 563-6.
21. Van der Auwera BJ, Vandewalle CL, Schuit FC et al. CTLA-4 gene polymorphism confers susceptibility to insulin-dependent diabetes mellitus (IDDM) independently from age and from other genetic or immune disease markers. Clin Exp Immunol 1997; 110: 98-103.
22. Gonzalez-Escribano MF, Rodriguez R, Valenzuela A, Garcia A, Garcia-Lozano JR, Nunez-Roldan A. CTLA-4 polymorphisms in Spanish patients with rheumatoid arthritis. Tissue Antigens 1999; 53: 296-300.
23. Harbo HF, Celius EG, Vartdal F, Spurkland A. CTLA-4 promoter and exon 1 dimorphisms in multiple sclerosis. Tissue Antigens 1999; 53: 106-10.
24. Brophy K, Ryan AW, Thornton JM et al. Haplotypes in the CTLA4 region are associated with coeliac disease in the Irish population. Genes Immun 2006; 7: 19-26.
25. Astermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK, THE MIBS STUDY GROUP. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 2007; 5: 263-5.
26. Armitage P. Tests for linear trends in proportions and frequencies. Biometrics 1955; 11: 375-86.
27. Heward J, Gough SC. Genetic susceptibility to the development of autoimmune disease. Clin Sci (Lond) 1997; 93: 479-91. Review.
28. Kristiansen OP, Larsen ZM, Pociot F. CTLA-4 in autoimmune diseases: A general susceptibility gene to autoimmunity? Genes Immun 2000; 1: 170-84.
29. Ligers A, Teleshova N, Masterman T, Huang WX, Hillert J. CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun 2001; 2: 145-52.
30. Kouki T, Sawai Y, Gardine CA, Fisfalen ME, Alegre ML, DeGroot LJ. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 2000; 165: 6606-11.
31. Anjos S, Nguyen A, Ounissi-Benkalha H, Tessier MC, Polychronakos C. A common autoimmunity predisposing signal peptide variant of the cytotoxic T-lymphocyte antigen 4 results in inefficient glycosylation of the susceptibility allele. J Biol Chem 2002; 277: 46478-86.
32. Roncarolo MG, Levings MK. The role of different subsets of T regulatory cells in controlling autoimmunity. Curr Opin Immunol 2000; 12: 676-83.
33. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH. Identification and functional characterization of human cd4(+)cd25(+)tcells with regulatory properties isolated from peripheral blood. J Exp Med 2001; 193: 1285-94.
34. Lim HW, Hillsamer P, Banham AH, Kim CH. Direct suppression of B cells by CD4+ CD25+ regulatory T cells. J Immunol 2005; 175: 4180-3.
35. Sullivan TJ, Letterio JJ, van Elsas A et al. Lack of a role for transforming growth factor-beta in cytotoxic T lymphocyte antigen-4-mediated inhibition of T cell activation. Proc Natl Acad Sci USA 2001; 98: 2587-92.
36. Sakaguchi S. Regulatory cells: Meden Agan. Immological Reviews. 2006; 212: 5-7.
37. Sansom DM, Walker LSK. The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immological Reviews. 2006; 212: 131-48.
38. Liu H, Hu B, Xu D, Liew FY. CD4(+)CD25(+) Regulatory T Cells Cure Murine Colitis: The Role of IL-10, TGF-beta, and CTLA4. J Immunol 2003; 171: 5012-7.
39. Brusko TM, Wasserfall CH, Agarwal A, Kapturczak MH, Atkinson MA. An integral role for Heme oxygenase -1 and carbon monoxide in maintaining peripheral tolerance by cd4+cd25+regulatory cells. J Immunol 2005; 174: 5181-6. Review.